Yue Y. Xie

300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Progressive pseudorheumatoid dysplasia involving a novel CCN6 mutation: a case report.

Progressive pseudorheumatoid dysplasia involving a novel CCN6 mutation: a case report.

Journal: Frontiers in immunology

Published: June 10, 2024

The protective effects of hyperoside on Ang II-mediated apoptosis of bEnd.3 cells and injury of blood-brain barrier model in vitro.

The protective effects of hyperoside on Ang II-mediated apoptosis of bEnd.3 cells and injury of blood-brain barrier model in vitro.

Journal: BMC complementary medicine and therapies

Published: November 25, 2021

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.

Journal: Chinese medical journal

Published: December 16, 2020

Comparison of intra-articular injection of parecoxib vs oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis.

Comparison of intra-articular injection of parecoxib vs oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis.

Journal: World journal of clinical cases

Published: September 30, 2019

Clinical efficacy of intra-articular parecoxib injection for the treatment of early knee osteoarthritis

Clinical efficacy of intra-articular parecoxib injection for the treatment of early knee osteoarthritis

Journal: Zhongguo gu shang = China journal of orthopaedics and traumatology

Published: March 11, 2019

Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients.

Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients.

Journal: International journal of clinical and experimental pathology

Published: December 11, 2017

TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.

TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.

Journal: Leukemia research

Published: August 29, 2016

TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.

TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: July 13, 2016

Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: May 07, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026